290 related articles for article (PubMed ID: 25836351)
1. Relapse in FEV1 Decline After Steroid Withdrawal in COPD.
Kunz LIZ; Postma DS; Klooster K; Lapperre TS; Vonk JM; Sont JK; Kerstjens HAM; Snoeck-Stroband JB; Hiemstra PS; Sterk PJ;
Chest; 2015 Aug; 148(2):389-396. PubMed ID: 25836351
[TBL] [Abstract][Full Text] [Related]
2. Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids.
Kunz LI; Ten Hacken NH; Lapperre TS; Timens W; Kerstjens HA; van Schadewijk A; Vonk JM; Sont JK; Snoeck-Stroband JB; Postma DS; Sterk PJ; Hiemstra PS;
Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 28049170
[TBL] [Abstract][Full Text] [Related]
3. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
[TBL] [Abstract][Full Text] [Related]
4. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
Lapperre TS; Snoeck-Stroband JB; Gosman MM; Jansen DF; van Schadewijk A; Thiadens HA; Vonk JM; Boezen HM; Ten Hacken NH; Sont JK; Rabe KF; Kerstjens HA; Hiemstra PS; Timens W; Postma DS; Sterk PJ;
Ann Intern Med; 2009 Oct; 151(8):517-27. PubMed ID: 19841453
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of salmeterol and fluticasone propionate alone and in combination on airway blood flow in patients with asthma.
Mendes ES; Rebolledo P; Wanner A
Chest; 2012 May; 141(5):1184-1189. PubMed ID: 21980058
[TBL] [Abstract][Full Text] [Related]
6. Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.
Fenton C; Keating GM
Drugs; 2004; 64(17):1975-96. PubMed ID: 15329047
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
[TBL] [Abstract][Full Text] [Related]
8. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change.
Jones PW; Anderson JA; Calverley PM; Celli BR; Ferguson GT; Jenkins C; Yates JC; Vestbo J; Spencer MD;
Respir Res; 2011 May; 12(1):71. PubMed ID: 21627828
[TBL] [Abstract][Full Text] [Related]
9. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
[TBL] [Abstract][Full Text] [Related]
10. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
11. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
[TBL] [Abstract][Full Text] [Related]
12. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
Magnussen H; Disse B; Rodriguez-Roisin R; Kirsten A; Watz H; Tetzlaff K; Towse L; Finnigan H; Dahl R; Decramer M; Chanez P; Wouters EF; Calverley PM;
N Engl J Med; 2014 Oct; 371(14):1285-94. PubMed ID: 25196117
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.
Jenkins CR; Jones PW; Calverley PM; Celli B; Anderson JA; Ferguson GT; Yates JC; Willits LR; Vestbo J
Respir Res; 2009 Jun; 10(1):59. PubMed ID: 19566934
[TBL] [Abstract][Full Text] [Related]
14. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
Tonnel AB; Tillie-Leblond I; Attali V; Bavelele Z; Lagrange O
Respir Med; 2011 Feb; 105(2):250-8. PubMed ID: 20702076
[TBL] [Abstract][Full Text] [Related]
16. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD.
Rossi A; van der Molen T; del Olmo R; Papi A; Wehbe L; Quinn M; Lu C; Young D; Cameron R; Bucchioni E; Altman P
Eur Respir J; 2014 Dec; 44(6):1548-56. PubMed ID: 25359348
[TBL] [Abstract][Full Text] [Related]
17. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
18. Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity.
van den Berge M; Steiling K; Timens W; Hiemstra PS; Sterk PJ; Heijink IH; Liu G; Alekseyev YO; Lenburg ME; Spira A; Postma DS
Thorax; 2014 Jan; 69(1):14-23. PubMed ID: 23925644
[TBL] [Abstract][Full Text] [Related]
19. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial.
Snoeck-Stroband JB; Lapperre TS; Sterk PJ; Hiemstra PS; Thiadens HA; Boezen HM; Ten Hacken NH; Kerstjens HA; Postma DS; Timens W; Sont JK;
PLoS One; 2015; 10(12):e0143793. PubMed ID: 26659582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
